TNFRSF14

Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million

Retrieved on: 
Monday, November 7, 2022
HVEM, Company, Private Securities Litigation Reform Act, TNFRSF3, Therapy, LLC, CD160, Sale, BTLA, Armistice, TNFRSF14, Board, End-user license agreement, GLOBE, HSV, Safety, TNFSF14, COVID-19, Janssen Pharmaceuticals, Asset purchase agreement, Nasdaq, ES, Herpesvirus entry mediator, PEAK, Forward-looking statement, Inflammatory Bowel Diseases, Drug development, License, Assignment, NEA, SEC, Autoimmunity, Patient, MD, Pharmaceutical industry, Vaccine

Once completed, we will have raised $20 million of nondilutive funding since August.

Key Points: 
  • Once completed, we will have raised $20 million of nondilutive funding since August.
  • The purchase agreement contains customary representations and warranties and covenants of the Company and ES.
  • Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT network.
  • ES Therapeutics is a privately held global pharmaceutical company focused on the development of therapeutics to treat certain neurological disorders.

Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage

Retrieved on: 
Tuesday, September 6, 2022
Sanford Burnham Prebys Medical Discovery Institute, CA, COVID-19, Inflammation, Safety, HVEM, IND, TNFRSF14, Therapy, NASDAQ, Autoimmunity, TNFRSF3, Board, Director, Lead, Asthma, HSV, SEC, Patent, MD, GLOBE, BTLA, Immune system, Attention, PEAK, Inflammatory Bowel Diseases, TNFSF14, Herpesvirus entry mediator, NEA, Hector Avalos, Private Securities Litigation Reform Act, CD160, Drug development, Forward-looking statement, Patient, Vaccine, Pharmaceutical industry

In June 2021, Avaloacquired rights to the BTLA fusion protein technology discovered by Dr. Carl Ware and colleagues at the Sanford Burnham Prebys in La Jolla, CA.

Key Points: 
  • In June 2021, Avaloacquired rights to the BTLA fusion protein technology discovered by Dr. Carl Ware and colleagues at the Sanford Burnham Prebys in La Jolla, CA.
  • Avalo is becoming a world-leader through our collaboration with Dr. Ware in this field with two high quality biologic drug candidates that address critical components of the LIGHT-signaling network.
  • AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein.
  • Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT network.

Avalo to Present at the H.C. Wainwright Global Investment Conference

Retrieved on: 
Thursday, September 1, 2022
COVID-19, HVEM, TNFRSF14, Therapy, Autoimmunity, Board, HSV, SEC, GLOBE, Conference, BTLA, Nasdaq, TNFSF14, Investor, Herpesvirus entry mediator, Private Securities Litigation Reform Act, CD160, Drug development, Forward-looking statement, Patient, Pharmaceutical industry

WAYNE, Pa. and ROCKVILLE, Md., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference being held September 12-14, 2022.

Key Points: 
  • WAYNE, Pa. and ROCKVILLE, Md., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference being held September 12-14, 2022.
  • The pre-recorded formal presentation will be made available on Monday, September 12, 2022 at 7:00 AM ET.
  • A webcast of the pre-recorded presentation can be accessed under the News/Events page in the Investors section of the Companys website, www.avalotx.com .
  • Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network.

Trigone Pharma Announces a Strategic Collaboration with 4C Biomed to Develop a Novel Treatment for High-Grade Bladder Cancer

Retrieved on: 
Monday, September 20, 2021
AUA, HVEM, Patent, Bladder cancer, American Urological Association, Solution, Therapy, TNFRSF14, Cancer, Patient, IC/BPS, PCT, MD, Trigone, InterAction Council of Former Heads of State and Government, Immune system, Immunotherapy, CEO, Mab, Urinary bladder, Science, BTLA, MBA, Drug development, Pharming, D, Urologic disease, NMIBC, Epithelium, HSV, GLOBE, Pharmaceutical industry, Vaccine, Medical imaging

RAANANA, Israel, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Trigone Pharma (Trigone), a pharmaceutical company pioneering prolonged intravesical treatment combined with targeted therapies for the treatment of bladder cancer, today announced a collaboration with 4C Biomed, to develop an innovative treatment for bladder cancer.

Key Points: 
  • RAANANA, Israel, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Trigone Pharma (Trigone), a pharmaceutical company pioneering prolonged intravesical treatment combined with targeted therapies for the treatment of bladder cancer, today announced a collaboration with 4C Biomed, to develop an innovative treatment for bladder cancer.
  • The collaboration will focus on local administration of 4C Biomeds anti 4CB-1 as an innovative treatment for high-grade non-muscle invasive bladder cancer.
  • Trigone Pharma, a pharmaceutical company dedicated to developing novel solutions that treat bladder cancers and urologic diseases, and 4C Biomed, an early-stage biomed R&D group specializing in immuno-oncology and auto-immunity today announced a strategic collaboration agreement to advance novel intravesical immunotherapy, which is delivered directly into the bladder, for the treatment of high-grade non-muscle invasive bladder cancer (HG-NMIBC).
  • Trigone Pharma is dedicated to developing and commercializing novel therapeutics to treat patients suffering from interstitial cystitis/bladder pain syndrome (IC/BPS), bladder cancer (NMIBC), and other related bladder conditions.